University of Nevada, Reno

Opthea to Host Key Opinion Leader Event on Sozinibercept (OPT-302) in Wet Age-Related Macular Degeneration on April 3, 2024

Retrieved on: 
Tuesday, March 19, 2024
Retina, University of Nevada, Reno, Houston Methodist Hospital, Webcast, Associate, ASX, KOL, University, Doctor of Philosophy, MBA, University of Illinois Urbana-Champaign, Shore, AMD, FACS, Medicine, Pharmaceutical industry

Additionally, Opthea will provide a strategic outlook.

Key Points: 
  • Additionally, Opthea will provide a strategic outlook.
  • A live question and answer session will follow the formal presentations.
  • To register for this live webcast, click here .
  • A replay of the webcast will be made available on the Company’s website.

Pan American Energy Announces the Commencement of Metallurgical Testing on Core Samples From the Horizon Lithium Project

Retrieved on: 
Thursday, March 14, 2024
Lithium, Element, Temperature, Technical report, Horizon, University of Nevada, Reno, Boron, Reno 1868 FC, Calcium, ICP, News, Sodium, University, LCE, Magnesium, Pan-American, Assessment, UNR

CALGARY, Alberta, March 14, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce the commencement of comprehensive metallurgical testing at University of Nevada, Reno ("UNR").

Key Points: 
  • CALGARY, Alberta, March 14, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce the commencement of comprehensive metallurgical testing at University of Nevada, Reno ("UNR").
  • The Company delivered 46 individual lithium-bearing core samples from twelve separate drill holes at the Horizon Lithium Project (“Horizon”), located in the Big Smoky Valley, Esmeralda County, Nevada.
  • The twelve represented drill holes were part of the Phase 1 and Phase 2 drilling campaigns completed by Pan American at Horizon in 2023.
  • Jason Latkowcer, Chief Executive Officer, commented, “The commencement of the metallurgical research and evaluation on the Horizon core samples is a big step forward for the Company.

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on: 
Wednesday, April 3, 2024
Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points: 
  • In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
  • This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
  • This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
  • WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

SPHERE LAUNCHES "SPHERE XO STUDENT DESIGN CHALLENGE" A FIRST-OF-ITS-KIND PARTNERSHIP WITH THE LAS VEGAS COMMUNITY MARKING THE FIRST TIME MEMBERS OF THE GENERAL PUBLIC WILL SEE THEIR ART FEATURED ON THE EXOSPHERE

Retrieved on: 
Thursday, March 14, 2024
UNLV, Clark County School District, Mathematics, CCSD, VR, University of Nevada, Reno, Learning, Science, Partnership, Education, Exosphere, XO, University, Student, SPHR, Curriculum, Interim, SPHERE, LED, Tutoring

LAS VEGAS, March 14, 2024 /PRNewswire/ -- Sphere Entertainment Co. (NYSE: SPHR) today announced the inaugural Sphere XO Student Design Challenge – a first-of-its-kind partnership with the greater Las Vegas community that for the very first time, gives select members of the general public the opportunity to see their art featured on the Exosphere. The Sphere XO Student Design Challenge is a collaboration between Sphere and the Clark County School District (CCSD) and University of Nevada, Las Vegas (UNLV) that will provide more than 100,000 Clark County-based students with an unprecedented opportunity to create art for the Exosphere. Eight student winners ranging from elementary school through college will be chosen by a combination of voting by the general public on thesphere.com, and selected by professional artists who have designed for the Exosphere, including Refik Anadol and Michela Picchi. The Sphere XO Student Design Challenge, which will kick off this month, will be themed around the 4th of July, with winning students' artwork debuting on the Exosphere on July 4, 2024, which will also mark the one-year anniversary of the first illumination of the Exosphere. In addition, winning high school and UNLV students will receive a $10,000 educational scholarship from Sphere. Winning elementary and middle school students will earn a $10,000 donation from Sphere for their school's art program to further art education in public schools, as well as tickets for their entire school to attend The Sphere Experience this Fall.

Key Points: 
  • In addition, winning high school and UNLV students will receive a $10,000 educational scholarship from Sphere.
  • "Sphere XO Student Design Challenge is an opportunity for us to engage Las Vegas students by introducing them to Sphere's technology, and meaningfully give back to the community by inspiring its future."
  • With Sphere's XO Student Design Challenge, our students get to explore innovation through art via hands-on learning."
  • The largest LED screen on Earth, the Exosphere consists of approximately 1.2 million LED pucks, spaced eight inches apart.

Pan American Energy Partners With The University Of Nevada, Reno For Comprehensive Metallurgical Testing And Research

Retrieved on: 
Monday, March 4, 2024
Lithium, Magnesium, Temperature, Sustainability, News, Reno 1868 FC, University of Nevada, Reno, Assessment, Calcium, Boron, University, Element, UNR, Horizon Project, Earth science, ICP, Assistant professor, Sodium, Metallurgy, Partnership

CALGARY, Alberta, March 04, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce it has partnered with the University of Nevada, Reno ("UNR") for comprehensive metallurgical testing on sedimentary and hard rock samples provided by the Company.

Key Points: 
  • CALGARY, Alberta, March 04, 2024 (GLOBE NEWSWIRE) -- Pan American Energy Corp. (CSE: PNRG | OTCQB: PAANF | FRA: SS60) ("Pan American” or the "Company") is pleased to announce it has partnered with the University of Nevada, Reno ("UNR") for comprehensive metallurgical testing on sedimentary and hard rock samples provided by the Company.
  • Jason Latkowcer, Chief Executive Officer, commented, “We are thrilled to announce our partnership with the esteemed University of Nevada, Reno, which is world renowned for its lithium expertise.
  • This partnership marks a significant stride towards the development of a preliminary economical assessment at the Horizon Lithium Project.
  • We will also benefit from UNR’s expertise in testing core samples from the Big Mack Lithium Project.

Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD

Retrieved on: 
Thursday, February 8, 2024
Chorioretinitis, Injection, Principal, Inflammation, Life, Adverum Biotechnologies, VEGF, AMD, Partner (business rank), Vasculitis, Patient, Safety, Paratriathlon, Prednisone, University of Nevada, Reno, Intraocular pressure, Data, Webcast, University, Retinitis, M.A, Clinical research, CST, Vascular occlusion, Pharmaceutical industry

These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.

Key Points: 
  • These data are being presented by Dr. Arshad Khanani today at the 47th Annual Meeting of the Macula Society.
  • “Wet AMD is a leading cause of blindness in people over the age of 65, requiring life-long anti-VEGF injections.
  • Our goal with Ixo-vec is to provide patients virtually injection-free management of their wet AMD lasting years and potentially for life,” stated Laurent Fischer, M.D., president and chief executive officer of Adverum Biotechnologies.
  • The LUNA trial builds on our experience with the OPTIC study, where landmark 2-year data was recently published in The Lancet’s eclinicalmedicine.

Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024

Retrieved on: 
Thursday, February 1, 2024
AMD, Safety, Medicine, University of Nevada, Reno, Weill Cornell Medicine, News, LUNA, Adverum Biotechnologies, University, M.A, Webcast, Clinical research, Pharmaceutical industry

REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review preliminary efficacy and safety data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) on Thursday, February 8th, 2024 at 8:00am ET. The webcast will include Szilard Kiss, M.D., Professor of Ophthalmology at Weill Cornell Medical College and an investigator in Adverum’s LUNA Phase 2 study. Adverum will further detail these preliminary results at the 47th Annual Meeting of the Macula Society. The preliminary LUNA results will include safety and efficacy data at both the 2E11 and 6E10 dose levels. LUNA was fully enrolled in August 2023.

Key Points: 
  • The webcast will include Szilard Kiss, M.D., Professor of Ophthalmology at Weill Cornell Medical College and an investigator in Adverum’s LUNA Phase 2 study.
  • Adverum will further detail these preliminary results at the 47th Annual Meeting of the Macula Society.
  • The preliminary LUNA results will include safety and efficacy data at both the 2E11 and 6E10 dose levels.
  • Adverum will host a conference call and webcast on Thursday, February 8th, 2024 at 8:00 am ET to discuss the preliminary safety and efficacy data from the LUNA Phase 2 study of Ixo-vec.

4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden

Retrieved on: 
Monday, January 29, 2024
PRISM, Angiogenesis, Patient, Science, Clinical research, University, Medicine, M.A, Conference, AMD, Webcast, University of Nevada, Reno, Clinical trial, Pharmaceutical industry

Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024 during Session VI (3:30 to 5:00 p.m.

Key Points: 
  • Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 Conference on Saturday, February 3, 2024 during Session VI (3:30 to 5:00 p.m.
  • ET)
    Company to host webcast on Monday, February 5, 2024 at 8:00 a.m.
  • Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial, will also present in the webcast and be available for Q&A.
  • An archived copy of the webcast will be available for up to one year by visiting the “Investors & Media” section of the 4DMT website at the following link: https://ir.4dmoleculartherapeutics.com/events .

Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024

Retrieved on: 
Monday, January 22, 2024
Dexamethasone, Patient, Telecanthus, TNF, University, Diabetic retinopathy, OCS, Inflammation, University of Nevada, Reno, DED, Retina, DME

Please click here to attend the event either in-person or virtually.

Key Points: 
  • Please click here to attend the event either in-person or virtually.
  • Location details for in-person attendance will be provided upon registration.
  • (Director, Oculis’ Board) and Riad Sherif, M.D.
  • In addition, management will provide a brief 2023 review and business outlook for 2024.

Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema

Retrieved on: 
Monday, December 18, 2023
Stage 2, DME, Pain, Macular edema, Inflammation, University, CST, Week, OCS, Telecanthus, University of Nevada, Reno, Patient, Safety, Diabetic retinopathy, Paratriathlon, Pharmaceutical industry

DIAMOND-1 (DIAbetic Macular edema patients ON a Drop) is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients.

Key Points: 
  • DIAMOND-1 (DIAbetic Macular edema patients ON a Drop) is a Phase 3, two-stage, double-masked, randomized, multi-center trial to assess the efficacy and safety of OCS-01 eye drops in DME patients.
  • The primary objective of the 3-month Stage 1 was to select the optimal dosing regimen (n=148).
  • Furthermore, 27.4% of patients in the OCS-01 group achieved ≥15-letter improvement in BCVA from baseline vs. 7.5% in the vehicle group at Week 12 (p=0.009).
  • OCS-01 eye drops have emerged as a potential solution for this unmet need, and the encouraging results from Stage 1 of the DIAMOND-1 Phase 3 trial support this outlook.